drugset / Trial / NCT02110654

Comparison of Daily Mometasone Furoate Nasal Spray Alone Versus a Combination With Montelukast for Treatment of Chronic Rhinosinusitis With Asthma After Functional Endoscopic Sinus Surgery

NCT02110654

RandomizedParallel-groupSingle-blindTreatment

Summary

1. objectives. To compare the efficacy and the safety of mometasone furoate nasal spray (MFNS; Nasonex 200μg, daily) alone versus a combination with montelukast (singulair 10mg, daily) in chronic rhinosinusitis (CRS) with asthma after functional endoscopic sinus surgery (FESS) for improvement the clinical control of CRS 2. the clinical hypotheses. The investigators hypothesize that postoperative combined montelukast and MFNS can better improve clinical control of CRS concomitant with asthma after FESS compared with MFNS alone. 3. study design This study is a 9-month randomized, open-label, controlled interventional study.

Timeline

Start
2014-06
Primary completion
2020-11-01
Completion
2020-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Mometasone furoate Other / unclassified 200 ug Intranasal
Subject Montelukast Other / unclassified 10 mg Oral